A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
Sponsor: Achieve Life Sciences
Terminated
Unable to enroll due to criteria for stable baseline pain
This PHASE3 trial investigates Castrate-Resistant Prostate Cancer and Hormone Refractory Prostate Cancer and is currently terminated or withdrawn. Achieve Life Sciences leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Sep 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Mar 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Achieve Life Sciences
- Teva Pharmaceuticals USA
For direct contact, visit the study record on ClinicalTrials.gov .